Martin Shkreli and Turing Pharmaceuticals are not the only instance where a previously inexpensive generic drug increased in price by more than 400%, said John Bennett, MD, FACC, FACP, president and CEO of CDPHP.
Martin Shkreli and Turing Pharmaceuticals are not the only instance where a previously inexpensive generic drug increased in price by more than 400%, said John Bennett, MD, FACC, FACP, president and CEO of CDPHP.
Transcript (modified)
Rising drug costs have become a bigger focus in the last year, but was this a growing issue that was just ignored until now?
So I think that, for a number of years, particularly through the Great Recession, we had pharmaceutical price trends that were not that excessive. Now a lot of that was really because we moved to a lot of generic drugs and that kind of window has disappeared.
So most companies now have 85%-90% generic prescribing and what we’re seeing, coupled with the explosion of specialty drugs, what we’re seeing is that even though drugs are prescribed generically, we’re seeing that there are many classes which have only 2, maybe 3, generic drug makers, and they are uniformly increasing the prices.
We’re suddenly seeing this huge increase not only in specialty and brand-name drugs, but in generic drugs. People are suddenly acquiring these orphan drugs which were very cheap or even some regular non-orphan drugs—drugs that are used by a wide segment of the population which previously were very cheap—they are acquiring those companies cheaply and just jacking up the price.
So people have to understand for instance that, you know, everyone is familiar with Martin Shkreli who jacked up the price. We could name a hundred instances where previously very inexpensive generic drugs have gone up 400%-500% so that is not a unique circumstance. I think we’re seeing this now and that is what has kind of blossomed.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More